Bacteriophages Therapy Market

1
Global Bacteriophage Therapy Market Is Estimated
To Witness High Growth Owing To Increasing
Prevalence of Antibiotic Resistance and
Opportunities in Developing Nations The global
bacteriophage therapy market is estimated to be
valued at US1,148.6 million in 2020 and is
expected to exhibit a CAGR of 3.7 over the
forecast period 2020-2030, as highlighted in a
new report published by Coherent Market
Insights. A) Market Overview Bacteriophage
therapy involves the use of bacteriophages, which
are viruses that specifically target and kill
bacteria. These phages can be used to treat
various bacterial infections, including those
that are resistant to antibiotics. The therapy
is being explored as an alternative to
antibiotics due to the increasing prevalence of
antibiotic resistance. Bacteriophage therapy has
shown promising results in preclinical and
clinical trials, and several companies are
investing in research and development to
commercialize phage- based therapeutics. B)
Market Dynamics The market dynamics of the
global market are driven by two key factors. The
first driver is the increasing prevalence of
antibiotic resistance. The overuse and misuse of
antibiotics have led to the emergence of
drug-resistant bacterial strains, which pose a
serious threat to public health. Bacteriophage
therapy offers a potential solution to this
problem by providing a targeted and effective
treatment option for drug- resistant infections.
The second driver is the increasing investments
in research and development of bacteriophage
therapy. Several pharmaceutical companies and
biotech startups are actively investing in the
development of phage-based therapeutics. For
example, Armata Pharmaceuticals, Inc. is
developing a phage-based therapy for the
treatment of drug-resistant infections, including
those caused by Pseudomonas aeruginosa. These
investments are expected to drive the growth of
the bacteriophage therapy market. C) Segment
Analysis In terms of application, the
therapeutics segment is expected to dominate the
global market. Bacteriophage therapeutics have
the potential to revolutionize the treatment of
bacterial infections, especially those that are
resistant to antibiotics. The therapeutics
segment is expected to witness high growth due
to increasing research and development activities
and the growing need for effective treatments
for antibiotic-resistant infections. D) PEST
Analysis - Political The use of bacteriophage
therapy may require regulatory approvals from
government authorities. The regulatory landscape
and policies related to the use of phage-based
therapeutics may vary across different
countries. - Economic The growing burden of
antibiotic-resistant infections has significant
economic implications. The high costs associated
with hospitalization, treatment, and management
of drug- resistant infections create a strong
demand for effective therapies, such as
bacteriophage therapy.
2
- Social The increasing awareness about the
threat of antibiotic resistance among healthcare
professionals and the general public is driving
the adoption of alternative therapies, such as
bacteriophage therapy. Additionally, the growing
interest in personalized medicine and targeted
therapies is also boosting the demand for
phage-based therapeutics. - Technological
Advancements in biotechnology and genomics have
facilitated the development and production of
specific phages for targeted therapy. Gene
sequencing technologies have enabled the
identification and isolation of phages that are
effective against specific bacterial strains.
E) Key Takeaways - The global bacteriophage
therapy market is expected to witness high
growth, exhibiting a CAGR of 3.7 over the
forecast period, due to increasing prevalence of
antibiotic resistance and opportunities in
developing nations. - In terms of regional
analysis, North America is expected to dominate
the global market. The region has a
well-established healthcare infrastructure, a
high prevalence of antibiotic-resistant
infections, and a strong presence of
pharmaceutical and biotech companies focusing on
research and development of phage-based
therapeutics. - Key players operating in the
global bacteriophage therapy market include
Armata Pharmaceuticals, Inc., Eliava
Biopreparations Ltd., Pherecydes Pharma,
Intralytix, Inc., Phagelux, Inc., Nextbiotics,
InnoPhage, Ltd, Locus Biosciences, Inc.,
TechnoPhage, Eligo Bioscience SA, Phagomed
Biopharma GmbH., PhagePro, Inc., Adaptive Phage
Therapeutics, Enbiotix, Inc., Intodeworld, Inc